Recombinant Human SDHA Protein, N-His (重组蛋白) | Bioss

货号:bs-103320P
产品详情
相关标记
相关产品
相关文献
常见问题

概述

产品编号
bs-103320P
英文名称
Recombinant Human SDHA Protein, N-His
英文别名
SDH2; Flavoprotein subunit of complex II; Succinate dehydrogenase [ubiquinone] flavoprotein subunit; mitochondrial; SDHA; SDHF; Fp
性状
Lyophilized
纯化方法
AC
理论分子量
70.31 kDa
储存液
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
SWISS
Gene ID
活性
Not tested
序列
44-664/664
物种
Human
标签
N-His
纯度
>90% as determined by SDS-PAGE.
表达系统
E.coli
复溶
Reconstitute in sterile water for a stock solution.
保存条件
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
注意事项
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
背景资料
In aerobic respiration reactions, succinate dehydrogenase (SDH) catalyzes the oxidation of succinate and ubiquinone to fumarate and ubiquinol. Four subunits comprise the SDH protein complex: a flavochrome subunit (SDHA), an iron-sulfur protein (SDHB), and two membrane-bound subunits (SDHC and SDHD) anchored to the inner mitochondrial membrane. Mutations to these subunits cause mitochondrial dysfunction, corresponding to several distinct disorders. Mutations in the membrane bound components may cause hereditary paraganglioma, while SDHA mutations are associated with juvenile encephalopathy as well as Leigh Syndrome, a severe neurological disorder. Inactivating mutations in SDHB correlate with inherited, but not necessarily sporadic, cases of pheochromocytoma.

相关产品

暂无相关产品

靶标

基因名
SDHA
蛋白名
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
功能
Defects in SDHA are a cause of mitochondrial complex II deficiency (MT-C2D). A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome.

同靶标产品

相关文献

常见问题